Konkurencja i konsument · 3.01.1997

Baxter International Inc.; Analysis to Aid Public Comment

In settlement of alleged violations of federal law prohibiting unfair or deceptive acts or practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would require, among other things, Baxter International (``Baxter''), an Illinois-based corporation, to divest its Autoplex product to a Commission-approved buyer, and to license Immuno International AG's (``Immuno'') product in development to a Commission- approved licensee within four months of the date Baxter signs the consent. This would resolve antitrust concerns raised by the proposed $463 million acquisition of Immuno by Baxter, which both manufacture a wide variety of biologic products derived from human blood plasma.